Get the Stockscreener App
36.81
0.88%
0.32
After Hours:
37.00
0.19
+0.52%
Vericel Corp stock is traded at $36.81, with a volume of 482.36K.
It is up +0.88% in the last 24 hours and up +7.82% over the past month.
Vericel Corp is a fully integrated commercial-stage biopharmaceutical company and a provider of therapies for the sports medicine and severe burn care markets. It markets cell therapy products in the United States, MACI (autologous cultured chondrocytes on porcine collagen membrane); Epicel (cultured epidermal autografts); and NexoBrid. The Company operates its business in the U.S. in one reportable segment; the research, product development, manufacture, and distribution of cellular therapies and specialty biologics for use in the treatment of specific conditions.
See More
Previous Close:
$36.49
Open:
$36.58
24h Volume:
482.36K
Relative Volume:
0.82
Market Cap:
$1.87B
Revenue:
$276.26M
Net Income/Loss:
$16.52M
P/E Ratio:
119.59
EPS:
0.3078
Net Cash Flow:
$24.75M
1W Performance:
+3.25%
1M Performance:
+7.82%
6M Performance:
-1.05%
1Y Performance:
-6.24%
1-Day Range:
$35.95
$37.17
1-Week Range:
$33.10
$37.17
52-Week Range:
$28.95
$45.97
Vericel Corp Stock (VCEL) Company Profile
Name
Vericel Corp
Sector
Industry
Phone
(734) 930-5555
Address
64 SIDNEY ST., CAMBRIDGE, MA
Compare VCEL vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
VCEL
Vericel Corp
|
36.81 | 1.86B | 276.26M | 16.52M | 24.75M | 0.3078 |
VRTX
Vertex Pharmaceuticals Inc
|
424.36 | 109.34B | 12.32B | 4.34B | 3.19B | 16.86 |
REGN
Regeneron Pharmaceuticals Inc
|
702.27 | 74.35B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
794.70 | 50.44B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
301.11 | 39.78B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
297.49 | 33.02B | 5.36B | 287.73M | 924.18M | 2.5229 |
Vericel Corp Stock (VCEL) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Sep-17-25 | Downgrade | BTIG Research | Buy → Neutral |
| Aug-09-24 | Initiated | Canaccord Genuity | Buy |
| Jun-20-24 | Initiated | TD Cowen | Buy |
| Jan-25-24 | Upgrade | Truist | Hold → Buy |
| Aug-08-23 | Upgrade | BTIG Research | Neutral → Buy |
| Nov-10-22 | Downgrade | BTIG Research | Buy → Neutral |
| Nov-09-22 | Downgrade | Truist | Buy → Hold |
| Oct-14-22 | Resumed | Stephens | Overweight |
| Jan-11-21 | Downgrade | Oppenheimer | Outperform → Perform |
| Dec-18-20 | Initiated | Stephens | Overweight |
| Sep-17-20 | Initiated | Truist | Buy |
| Oct-09-19 | Initiated | H.C. Wainwright | Buy |
| Feb-28-19 | Downgrade | Needham | Buy → Hold |
| Aug-08-18 | Reiterated | Needham | Buy |
| Jul-16-18 | Upgrade | Ladenburg Thalmann | Neutral → Buy |
| Apr-04-18 | Initiated | Leerink Partners | Outperform |
| Mar-06-18 | Downgrade | Ladenburg Thalmann | Buy → Neutral |
| Mar-06-18 | Reiterated | Needham | Buy |
| Mar-05-18 | Reiterated | BTIG Research | Buy |
| Jun-21-17 | Initiated | BTIG Research | Buy |
| Mar-13-17 | Reiterated | Needham | Buy |
| Dec-22-16 | Initiated | Piper Jaffray | Overweight |
| Nov-09-16 | Reiterated | Needham | Buy |
| Apr-05-16 | Downgrade | BofA/Merrill | Buy → Neutral |
| Mar-11-16 | Upgrade | Needham | Hold → Buy |
View All
Vericel Corp Stock (VCEL) Latest News
Global Stem Cell Therapy Market Set to Flourish at a CAGR of ~11% by 2034 Owing to the Technological Advancements and Favorable Regulations | DelveInsight - GlobeNewswire Inc.
MSN Money - MSN
Vericel Corp (NASDAQ:VCEL) Presents a Compelling Growth and Technical Setup Opportunity - ChartMill
Wall Street Analysts Think Vericel (VCEL) Could Surge 53.42%: Read This Before Placing a Bet - Yahoo Finance
Vericel (VCEL) director receives new RSU and stock option grants - Stock Titan
Vericel (NASDAQ: VCEL) director awarded RSUs and 8,000 stock options - Stock Titan
Vericel (NASDAQ: VCEL) director logs RSU conversion and new 8,000-share option grant - Stock Titan
Vericel (VCEL) director defers RSUs and receives new option grant - Stock Titan
Vericel (VCEL) director reports RSU vesting and new stock option awards - Stock Titan
Vericel (VCEL) investors back board slate, executive pay and PwC as auditor - Stock Titan
Conestoga Capital Advisors LLC Acquires 79,278 Shares of Vericel Corporation $VCEL - MarketBeat
Vericel Annual Meeting: Shareholders Elect Seven Directors, Approve Say-on-Pay and PwC Auditor - Yahoo Finance
Vanguard buys/holds 2.60M Vericel shares — Vericel (NASDAQ: VCEL) - Stock Titan
Vericel (VCEL) Expected to Announce Earnings on Thursday - MarketBeat
Vericel Corporation (NASDAQ:VCEL) Given Consensus Recommendation of "Moderate Buy" by Brokerages - MarketBeat
Vericel sets May 7 earnings call, with webcast replay through 2027 - Stock Titan
Vericel (NASDAQ:VCEL) Shares Down 7.1%Time to Sell? - MarketBeat
VCEL Forecast, Price Target & Analyst Ratings | VERICEL CORP (NASDAQ:VCEL) - ChartMill
VCEL Maintains Buy Rating -- Price Target Lowered to $42 by Trui - GuruFocus
Truist Cuts Price Target on Vericel to $42 From $48, Keeps Buy Rating - marketscreener.com
Vericel Corporation (VCEL) secures FDA approval for commercial manufacturing of MACI - MSN
Vericel Corporation (VCEL) Stock Price, News, Quote & History - Yahoo Finance
Critical Limb Ischemia Market: High-Growth Opportunities for Investors to 2034 – DelveInsight | Baxter, Ixaka, Hemostemix Inc., Caladrius Biosciences, Vericel Corporation, Helixmith, Lifecells, LLC - Barchart
Assessing Vericel (VCEL) Valuation After BARDA Awards Up To US$197 Million NexoBrid Contract - simplywall.st
Q3 2025 Vericel Corp Earnings Call Transcript - GuruFocus
Is Vericel Corporation (VCEL) Stock Trending Up | Price at $33.41, Down 1.82%Community Risk Signals - Cổng thông tin điện tử tỉnh Lào Cai
Winners Losers: What are the future prospects of Vericel Corporation2026 Major Catalysts & Smart Swing Trading Techniques - baoquankhu1.vn
Weekly Trades: Is Vericel Corporation part of any ETF2026 News Drivers & Precise Swing Trade Alerts - baoquankhu1.vn
Jonathan Mark Hopper Sells 3,472 Shares of Vericel (NASDAQ:VCEL) Stock - MarketBeat
Vericel (VCEL) CMO sells 3,472 shares after option exercise under 10b5-1 plan - Stock Titan
Why Smart Money Is Shifting From Clinical Data to Manufacturing Lines - Cantech Letter
After islet transplants, 10 diabetes patients stopped using insulin - Stock Titan
Aberdeen Group plc Has $21.03 Million Stock Position in Vericel Corporation $VCEL - MarketBeat
Analysts Set Vericel Corporation (NASDAQ:VCEL) Price Target at $56.00 - Defense World
Vericel Corporation (VCEL) Stock forecasts - Yahoo Finance UK
VCEL SEC FilingsVericel 10-K, 10-Q, 8-K Forms - Stock Titan
Allspring Global Investments Holdings LLC Cuts Position in Vericel Corporation $VCEL - marketbeat.com
Vericel Corporation (VCEL) Stock Forecasts - Yahoo Finance
Vericel Corporation (NASDAQ:VCEL) Given Consensus Rating of "Moderate Buy" by Brokerages - MarketBeat
VCEL Stock Analysis: Vericel Corporation 4.85% gain, 34.14 performance outlook - Newser
Vericel at TD Cowen Conference: Strong Growth and Strategic Expansion By Investing.com - Investing.com India
Vericel at TD Cowen Conference: Strong Growth and Strategic Expansion - Investing.com
Vericel (VCEL) Secures Lucrative Contract with Health and Human Services - GuruFocus
U.S. stockpile plans include NexoBrid under BARDA deal worth up to $197M - Stock Titan
MediWound and Vericel Secure Up to $197 Million BARDA Contract for NexoBrid® Procurement and Development - Quiver Quantitative
U.S. burn emergency stockpile gets NexoBrid in $197M BARDA pact - Stock Titan
[144] Vericel Corp SEC Filing - Stock Titan
Soleus discloses 2.55M Vericel shares (NASDAQ: VCEL) - Stock Titan
Vericel Corp (VCEL) Stock Price Quote Today & Current Price Chart - Capital.com
Vericel Corp (VCEL) Stock Price Quote Today & Current Price Chart | Capital.com Australia - Capital.com
Quarterly Trades: Is Vericel Corporation in a bullish channel2026 Market Mood & Free Verified High Yield Trade Plans - baoquankhu1.vn
Vericel Corp Stock (VCEL) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.14%
0.48%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):